Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.
Am J Clin Pathol
; 152(5): 675-685, 2019 10 07.
Article
em En
| MEDLINE
| ID: mdl-31305869
ABSTRACT
OBJECTIVES:
Increasingly, acute promyelocytic leukemia (APL) is treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This study characterizes bone marrow findings after ATRA/ATO therapy.METHODS:
Bone marrow biopsies from 16 patients treated with ATRA/ATO and seven patients treated with ATRA/chemotherapy (CTX) for APL were evaluated.RESULTS:
In ATRA/ATO cases, the marrow was likely to be hypercellular (79%) with a decreased myeloiderythroid (ME) ratio (88%), megaloblastoid maturation of erythroid precursors (100%), erythroid atypia (75%), and increased (88%) and atypical (75%) megakaryocytes. Significant myeloid atypia was only seen in extensive residual disease. The ATRA/CTX cases were less likely to be hypercellular (38%), have a ME ratio of 11 or less (0%), exhibit significant erythroid atypia (0%), or have increased (0%) or atypical (38%) megakaryocytes.CONCLUSIONS:
Bone marrow biopsies from patients treated with ATO have unusual but characteristic features. Despite variability in marrow findings, clinical outcomes were uniformly favorable.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Medula Óssea
/
Células da Medula Óssea
/
Leucemia Promielocítica Aguda
/
Trióxido de Arsênio
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article